Conceptus, Inc. (CPTS) Tops Q2 EPS by 2c; Guides FY11 Sales; Announces FDA Approval to Remove Nick Contraindication from Essure Procedure Instructions
Tweet Send to a Friend
Conceptus, Inc. (NASDAQ: CPTS) reported Q2 EPS of $0.01, $0.02 better than the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
